Valuation: Amgen Inc.

Market Cap 239B 1,231B 205B 192B 175B 331B 22,793B 334B 2,264B 882B 11,500B 898B 878B 38,084B P/E 2026 *
28x
P/E 2027 * 25x
Enterprise Value 281B 1,445B 240B 225B 206B 388B 26,748B 392B 2,657B 1,034B 13,495B 1,054B 1,031B 44,692B EV / Sales 2026 *
7.21x
EV / Sales 2027 * 6.84x
Free-Float
99.77%
Yield 2026 *
2.28%
Yield 2027 * 2.41%
1 day+0.82%
1 week+2.86%
Current month+16.41%
1 month+19.19%
3 months+32.59%
6 months+15.83%
Current year+23.35%
1 week 70.01
Extreme 70.01
82.26
1 month 68.26
Extreme 68.26
83.38
Current year 48.4
Extreme 48.4
83.38
1 year 48.4
Extreme 48.4
83.38
3 years 44.74
Extreme 44.74
83.38
5 years 37.52
Extreme 37.52
83.38
10 years 15.78
Extreme 15.780356
83.38
Manager TitleAgeSince
Chief Executive Officer 63 01/05/2012
Director of Finance/CFO 62 13/05/2010
Director of Finance/CFO 67 01/01/2020
Director TitleAgeSince
Chairman 63 01/01/2013
Director/Board Member 65 01/01/2012
Director/Board Member 71 01/01/2012
Change 5-day change 1-year change 3-year change Capi.($)
+0.82%+2.86% - - 240B
-1.06%+0.65%+77.42%+122.82% 1,111B
+0.53%+0.75%+53.10%+64.29% 658B
+0.48%+2.65%+28.06%+81.19% 467B
+0.92%+3.57%+43.82%+44.21% 369B
+1.25%+2.21%+26.77%+43.05% 301B
+3.02%+5.68%+4.24%+17.04% 256B
-0.36%+3.99%+53.31%+72.49% 240B
+2.86%+3.86%-16.20%-51.83% 207B
+1.38%+3.72%+30.33%+93.56% 182B
Average +0.98%+2.95%+33.43%+54.09% 421.22B
Weighted average by Cap. +0.46%+2.20%+45.99%+72.30%

Financials

2026 *2027 *
Net sales 38.94B 201B 33.37B 31.27B 28.56B 53.9B 3,712B 54.43B 369B 144B 1,873B 146B 143B 6,202B 40.2B 207B 34.44B 32.27B 29.48B 55.64B 3,832B 56.19B 381B 148B 1,933B 151B 148B 6,403B
Net income 8.6B 44.27B 7.37B 6.9B 6.31B 11.9B 820B 12.02B 81.43B 31.7B 414B 32.28B 31.58B 1,369B 9.39B 48.37B 8.05B 7.54B 6.89B 13B 896B 13.13B 88.97B 34.63B 452B 35.27B 34.5B 1,496B
Net Debt 41.49B 214B 35.55B 33.31B 30.43B 57.42B 3,955B 57.99B 393B 153B 1,995B 156B 152B 6,608B 35.83B 184B 30.7B 28.77B 26.28B 49.59B 3,416B 50.08B 339B 132B 1,723B 135B 132B 5,707B
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
25/08/26 BRL 81.36 +0.82% 443
21/08/26 BRL 80.70 +2.40% 142
20/08/26 BRL 78.81 -3.23% 307
19/08/26 BRL 81.44 +2.96% 97
18/08/26 BRL 79.10 +1.92% 102
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
34
Last Close Price
442.24USD
Average target price
388.48USD
Spread / Average Target
-12.16%

Quarterly revenue - Rate of surprise